Prevnar 13: Pneumococcal 13-valent Conjugate Vaccine
   

*Compared to Prevnar®
About the Importance of an Additional Dose of Prevnar 13®
Learn more
 

Home > Recommended by Doctors

Recommended by Doctors

Doctors at the Centers for Disease Control and Prevention (CDC) recommend that children under age 5 receive Prevnar 13®.

ACIP and AAP Recommendations

To help prevent invasive pneumococcal disease (IPD) in infants and young children, the CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend four doses of Prevnar 13® and a supplemental dose in children 15 months to five years of age who have received 4 doses of Prevnar® (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein)].

Click here to see the vaccination schedule for Prevnar 13®

Learn more about the AAP recommendation, visit healthychildren.org

Talk to your child's doctor about the risks and benefits of Prevnar 13®. Only a health care provider can decide if Prevnar 13® is right for your child.

Learn more: What is Prevnar 13®?

INDICATIONS FOR PREVNAR 13®

  • Prevnar 13® is a vaccine approved for use in children 6 weeks through 5 years for prevention of invasive disease (caused by the 13 strains of Streptococcus pneumoniae included in the vaccine) and ear infections (caused by 7 of the 13 strains)
  • Based upon immune responses to the vaccine, Prevnar 13® is also approved for adults 50 years and older for the prevention of pneumococcal pneumonia and invasive disease caused by the 13 vaccine strains
  • Prevnar 13® is not 100% effective and will only help protect against the 13 strains included in the vaccine
  • Effectiveness when given less than 5 years after a pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION

  • Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine
  • Children and adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response
  • A temporary pause of breathing following vaccination has been observed in some infants born prematurely
  • The most commonly reported serious adverse events in children were bronchiolitis (an infection of the lungs) (0.9%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%), and pneumonia (0.9%)
  • In infants and toddlers, the most common side effects were tenderness, redness or swelling at the injection site, irritability, decreased appetite, decreased or increased sleep, and fever
  • In adults, immune responses to Prevnar 13® were reduced when given with injected seasonal flu vaccine
  • In adults, the common side effects were pain, redness, or swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, chills, or rash
  • Ask your health care provider about the risks and benefits of Prevnar 13®. Only a health care provider can decide if Prevnar 13® is right for your child

You are encouraged to report negative side effects of vaccines to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see Prescribing Information for Prevnar 13® Adobe Reader

The immune response this schedule might be lower for the 6 additional strains (types 1, 3, 5, 6A, 7F, and 19A) than if your child had received the full 4 doses of Prevnar 13®.

Adobe Reader
The above Prescribing Information is available in PDF (portable document format).
PDF files require Adobe Reader; click here to download this free program.

Home  |  What is Prevnar 13®?  |  What is Pneumococcal Disease?
Broader Coverage* for Children Already Vaccinated with 4 Doses of Prevnar®  |  Vaccination Schedule For Prevnar 13®
Resources for Parents  |  Important Safety Information  |  Prescribing Information  |  For U.S. Health Care Professionals  |  Contact Us  |  Sitemap

PREVNAR® and PREVNAR 13® are registered trademarks of Wyeth LLC.
Wyeth Manufactured by Wyeth Pharmaceuticals Inc.   Marketed by Pfizer Inc.
PSP445810-01   © 2012 Pfizer Inc.   All rights reserved.   March 2012
0
This site is intended only for residents of the United States.
All rights reserved.
Please read our Privacy Policy and Terms and Conditions.
The product information provided in this site is intended for residents of the United States.
The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only
and is not intended to replace discussions with a health care provider.
All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.
Small Medium Large